PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

NEW YORK, June  15, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical diagnostics pioneer Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences (Nasdaq: EXAS), has joined its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), as a Strategic Advisor to assist with its commercial, regulatory, clinical trial and capital markets strategies.

Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor

NEW YORK, June  11, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), received preliminary gapfill payment determination for its EsoGuard™ Esophageal DNA Test (“EsoGuard”).

PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test

Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin

PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes

PAVMed Is About To Enter The Commercialization Phase

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript

Conference call to be held today at 4:30 p.m. Eastern time

PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update

PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts

NEW YORK, April  21, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its CarpX™ minimally invasive carpal tunnel device.

PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript

PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update

NEW YORK, April  02, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology, developed and marketed by its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”), was named a Silver winner of the 2020 Edison Best New Product Awards in the Medical/Dental category and Testing Solutions subcategory.

PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award

NEW YORK, March  31, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received $6.3 million in new gross proceeds from the prepayment of promissory notes issued in conjunction with a previously disclosed November 2019 private placement (the “Financing”). Maxim Group LLC acted as financial advisor to PAVmed in this transaction.

PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing

Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints

PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device

Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and frequent invasive endoscopies

PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops

PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ products

PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

NEW YORK, Feb.  11, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD).

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

NEW YORK, Jan.  13, 2020  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq Listing Rule 5550(a)(2) after 10 consecutive days with a closing bid price of at least $1 per share.

PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test

NEW YORK, Dec.  13, 2019  (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its CarpX™ first-in-human (FIH) 510(k) clinical safety study.

PAVmed Provides Update on CarpX™ Clinical Safety Study

PAVmed Has Multiple Paths To Growth

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript

Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time

PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update

Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology

PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products

Unprecedented six-month maintenance-free implant duration achieved

News for PAVmed Stock (PAVM)